This Merck division was only created about a year ago and Fujifilm is a recent addition to the biotech market with the purchase of another chemical company last year. As mergers and acquisitions go with the use of business intelligence, companies are aligning themselves with “like” or similar technologies in the race for generating more revenue but this one looks a little odd as now Fujifilm moves into a new area from imaging, where they have been most pronounced in healthcare. BD
Fujifilm Holdings Corp. will buy two units of Merck & Co. that make biopharmaceuticals as it targets growth in the health-care industry to make up for declining sales in cameras and film.
The Tokyo-based maker of imaging equipment and digital cameras will acquire laboratories in the U.S. and U.K. for 40 billion yen ($490 million), Nikkei English News reported today without saying where it got the pricing information. Toshihiro Matsumoto, a Fujifilm spokesman, confirmed the purchase by phone today, without giving a price.
he company will buy BioManufacturing Network Diosynth RTP LLC of Research Triangle Park, North Carolina, and MSD Biologics (U.K.) Ltd., based in Billingham, England. The deal for the units, which generate about 13 billion yen in sales a year, should be completed by early April, Matsumoto said.